Regeneron and Telix Forge Strategic Alliance for Radiopharmaceutical Development

Regeneron Pharmaceuticals (REGN) and Telix Pharmaceuticals (TLX) have announced a strategic partnership aimed at the joint development and commercialization of advanced radiopharmaceutical therapies. The alliance merges Regeneron's expertise in biologics and bispecific antibody discovery—specifically utilizing its VelocImmune mouse platform—with Telix's established radiopharmaceutical development platform and global supply chain. The collaboration will focus on multiple solid tumor targets from Regeneron's antibody portfolio. To support these efforts, the two companies plan to develop radio-diagnostics designed to enhance patient selection and the assessment of treatment responses, aligning with a shared commitment to precision oncology. Under the financial terms of the agreement, Telix will receive an initial $40 million upfront cash payment from Regeneron for access to its manufacturing platform across four initial therapeutic programs. Regeneron retains the option to expand the scope to include four additional programs via further upfront payments. Regarding commercialization, the partners intend to share global costs and potential profits equally, though Telix maintains the option to co-promote certain products. Should Telix choose to opt out of the co-funding model for a specific program, it becomes eligible for up to $535 million in development and commercial milestones, plus low double-digit royalties on future net sales. Additionally, the companies will jointly develop diagnostic assets. Telix will lead the commercialization of these diagnostics, while Regeneron will receive a designated percentage of the resulting profits.